The 5th International Neuroscience Summit for the Middle East, Africa and Russia (MEANS) is being held in Dubai.
The International Neurology Conference for the Middle East, Africa and Russia kicked off in Dubai, in cooperation with AbbVie, the global biopharmaceutical research and development company, with the participation of an elite group of international and national speakers and in the presence of several consultants, specialist physicians, researchers, professors and neurology experts from Gulf countries, Saudi Arabia, Egypt and Russia, in addition to several international, regional and local medical associations. The conference included several scientific lectures that discuss the latest research and treatment methods for many neurological diseases such as Parkinson's disease, migraine and post-stroke spasticity.
Dr. Abdulrazzaq Al-Bilali, Headache Specialist and Head of the Saudi Headache Chapter, Saudi Neurology Society, commended the continuous efforts of the organizers of this major conference and its success for the fifth consecutive year. Dr. Abdulrazzaq emphasized that scientific research is the cornerstone of progress in the field of neurology. He explained that headache is a health problem that significantly impacts people's lives and daily activities, and that significant developments have occurred in diagnostic methods and disease management. He emphasized that the future of patient care lies in innovation and evidence-based knowledge.
For his part, Dr. Suhail Al Rukun, consultant neurology, President of Emirates neurology Society in the United Arab Emirates, praised the large turnout at the conference, which included valuable medical discussions, workshops, and a review of the latest recommendations from clinical trials and research in this sector, in addition to presenting the best methods used in the management of patients with neurological diseases. Dr. Suhail added that this prominent scientific event is a good opportunity to exchange experiences and keep up with the latest developments in the neurology field. Organizing this summit for the fifth consecutive year embodies the ongoing commitment to enhancing medical knowledge and achieving the best treatment outcomes for patients. These initiatives help improve the quality of healthcare and open new horizons for improving patients' lives.
Mohammad Aboubakr, Vice President and General Manager of AbbVie's Middle East, Africa & Russia region, commended the launch of the fifth Neurology Summit, which highlighted the latest emerging scientific and medical developments. He emphasized that organizing the summit reflects AbbVie's commitment to enhancing scientific training and research programs and providing a high level of medical care to serve society members by providing what helps improve their quality of life. The company seeks to help make a real difference in patients' lives, as well as its commitment to raising awareness and health education for patients, and on the other hand, its focus on the fields of education, training and scientific research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Syyaha
15-06-2025
- Syyaha
The 5th International Neuroscience Summit for the Middle East, Africa and Russia (MEANS) is being held in Dubai.
The International Neurology Conference for the Middle East, Africa and Russia kicked off in Dubai, in cooperation with AbbVie, the global biopharmaceutical research and development company, with the participation of an elite group of international and national speakers and in the presence of several consultants, specialist physicians, researchers, professors and neurology experts from Gulf countries, Saudi Arabia, Egypt and Russia, in addition to several international, regional and local medical associations. The conference included several scientific lectures that discuss the latest research and treatment methods for many neurological diseases such as Parkinson's disease, migraine and post-stroke spasticity. Dr. Abdulrazzaq Al-Bilali, Headache Specialist and Head of the Saudi Headache Chapter, Saudi Neurology Society, commended the continuous efforts of the organizers of this major conference and its success for the fifth consecutive year. Dr. Abdulrazzaq emphasized that scientific research is the cornerstone of progress in the field of neurology. He explained that headache is a health problem that significantly impacts people's lives and daily activities, and that significant developments have occurred in diagnostic methods and disease management. He emphasized that the future of patient care lies in innovation and evidence-based knowledge. For his part, Dr. Suhail Al Rukun, consultant neurology, President of Emirates neurology Society in the United Arab Emirates, praised the large turnout at the conference, which included valuable medical discussions, workshops, and a review of the latest recommendations from clinical trials and research in this sector, in addition to presenting the best methods used in the management of patients with neurological diseases. Dr. Suhail added that this prominent scientific event is a good opportunity to exchange experiences and keep up with the latest developments in the neurology field. Organizing this summit for the fifth consecutive year embodies the ongoing commitment to enhancing medical knowledge and achieving the best treatment outcomes for patients. These initiatives help improve the quality of healthcare and open new horizons for improving patients' lives. Mohammad Aboubakr, Vice President and General Manager of AbbVie's Middle East, Africa & Russia region, commended the launch of the fifth Neurology Summit, which highlighted the latest emerging scientific and medical developments. He emphasized that organizing the summit reflects AbbVie's commitment to enhancing scientific training and research programs and providing a high level of medical care to serve society members by providing what helps improve their quality of life. The company seeks to help make a real difference in patients' lives, as well as its commitment to raising awareness and health education for patients, and on the other hand, its focus on the fields of education, training and scientific research
Daily Tribune
12-06-2025
- Daily Tribune
Writer first to die under Italy fast-track assisted suicide law
AFP | Rome A writer suffering from Parkinson's disease has become the first to die through medically assisted suicide under a fast-track regional law in Italy, campaigners said yesterday. Daniele Pieroni died at home on May 17, three months after the new legislation was passed by regional authorities in Tuscany, the pro-euthanasia Luca Coscioni Association said. The Italian Constitutional Court ruled in September 2019 that assisted suicide was allowed for patients in certain circumstances. But the national parliament has yet to adopt any legislation, which means that obtaining permission to die is difficult and can take years. In February, Tuscany -- ruled by the centre left -- became the first of Italy's 20 regions to set out its own rules streamlining and speeding up the request process. Prime Minister Giorgia Meloni's right-wing coalition is broadly against euthanasia and is challenging the Tuscan law in court. But any decision on that will come too late to affect Pieroni's choice. Born in 1961, the writer had been suffering from Parkinson's disease since 2008 and was forced to use a feeding tube for 21 hours a day, the Luca Coscioni Association said in a statement. 'The lethal drug was prepared at his home, which Daniele self-administered' in the presence of doctors and his family, the statement added. It has called on other regions in the Catholic-majority country to follow Tuscany's lead. 'Too many people continue to suffer or emigrate to die with dignity,' said the association. 'We invite all regions to act to guarantee freedom and respect for people's wishes.' Helping someone take their own life is technically illegal in Italy, punishable with between five and 12 years behind bars. But the Constitutional Court made an exception for those facing an incurable illness causing 'intolerable' physical or psychological suffering, where they are kept alive by life-support treatments but remain capable of making 'free and informed decisions'.
Syyaha
07-05-2025
- Syyaha
MOU between the Saudi Society of Dermatology and Dermatologic Surgery (SSDDS), AbbVie and Al Nahdi Medical Company
The Saudi Society of Dermatology and Dermatologic Surgery SSDDS, the leading professional body for dermatologists in Saudi Arabia, signed a Memorandum of Understanding with AbbVie Saudi Arabia, the global biopharmaceutical research and development company, and Al Nahdi Medical Company, the largest retail pharmacy chain in the Middle East and Africa. The MOU aims to collaborate on enhancing public health services, awareness programs, and advancing disease management through innovative healthcare solutions. The MOU also aims to strengthen the role of the Saudi Society of Dermatology through partnerships between the private and public entities to drive innovative healthcare solutions in line with Saudi Vision 2030. Dr. Abdullah Al-Aqeel, President of SSDDS, pointed out that the MOU primarily aims to collaborate on patient education and awareness campaigns, particularly on psoriasis and atopic dermatitis, their symptoms, and treatment options. It also aims to provide patients with access to accurate and culturally relevant educational materials. It also aims to train and support healthcare professionals by conducting training sessions and workshops in collaboration with SSDDS to hone the skills of dermatologists and healthcare providers on the latest developments in the treatment of atopic dermatitis and psoriasis. Dr. Maysa Ashmawy, Head of Dermatology at Saudi Ministry of Health, and a member of the Board of the Saudi Society of Dermatology and Dermatologic Surgery, emphasized the importance of such partnerships, which aim to improve healthcare services, and to contribute to research in collaboration with SSDDS, in addition to sharing insights with healthcare providers in line with national public health objectives. Dr. Afaf Al-Sheikh, Consultant and Head of the Dermatology Department at King Abdulaziz Medical City and the National Guard, commended the signing of the MOU, which aims to establish a collaborative framework to advance the management of psoriasis and atopic dermatitis in Saudi Arabia. She also emphasized the need to raise awareness of these cases, promote early diagnosis and treatment, and improve healthcare access and quality, in alignment with Saudi Vision 2030. She added that SSDDS as always, is fulfilling its developmental and training role by organizing professional training sessions for dermatologists and healthcare providers, facilitating research initiatives, and sharing insights on disease management trends. For his part, Dr. Ashraf Daoud, General Manager of AbbVie Saudi Arabia, emphasized AbbVie's efforts to collaborate with health authorities in the Kingdom to provide healthcare and awareness services, provide training resources, support healthcare professional education initiatives, and collaborate on patient awareness and outreach programs. He added, AbbVie's mission is to discover and deliver innovative medicines and solutions that solve today's serious health issues and address future medical challenges. The company also strives to make a remarkable impact on people's lives in several key therapeutic areas, including immunology, oncology and neuroscience.
